Once valued at more than $5B, Intarcia Therapeutics sees all of its execs depart and its final shot at FDA denied
The last members of its executive team have moved on, the phone number at its Boston-based HQ has been shut off, and as of earlier this month, the FDA has denied Intarcia Therapeutics’ final request for a hearing to re-review the company’s twice-rejected type 2 diabetes drug candidate and proprietary delivery system.
The letter from the FDA earlier this month caps a nearly five-year saga from when the FDA first rejected Intarcia’s twice-yearly type 2 diabetes drug, known as ITCA 650, after calling on the company to address extensive clinical deficiencies, and device and product quality-related issues.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.